coronavirus
largest
rna
virus
envelop
positivestrand
genom
kb
distribut
global
wide
rang
anim
human
coronavirus
classifi
four
genera
base
phylogenet
analysi
alphacoronavirus
betacoronavirus
gammacoronavirus
deltacoronavirus
strain
coronavirus
betacoronaviru
alphacoronaviru
caus
agent
common
cold
rare
sever
respiratori
diseas
newli
discov
human
coronavirus
occasion
associ
sever
lower
respiratori
tract
infect
infant
immunocompromis
patient
sarscov
lineag
b
betacoronaviru
merscov
novel
betacoronaviru
lineag
c
virus
appear
cross
speci
barrier
bat
human
bat
reservoir
mani
mammalian
coronavirus
variou
sarslik
coronavirus
found
bat
china
asia
europ
none
consid
direct
progenitor
sarscov
recent
howev
investig
china
report
whole
genom
sequenc
two
novel
bat
coronavirus
chines
horsesho
bat
close
relat
sarscov
receptorbind
domain
spike
protein
similar
sarscov
one
isol
bat
use
angiotensinconvert
enzym
human
civet
chines
horsesho
bat
cell
entri
sarscov
previous
shown
use
human
molecul
entri
receptor
outstand
featur
crossspeci
transmiss
thu
bat
slcovwivi
may
ancestor
viru
preced
evolut
sarscov
human
respiratori
epitheli
cell
human
main
target
sarscov
viru
also
found
immun
cell
circul
lymphocyt
macrophag
variou
organ
merscov
hand
use
human
bat
dipeptidyl
receptor
cell
entri
replic
rna
protein
synthesi
merscov
occur
human
airway
epitheli
cell
lung
fibroblast
microvascular
endothelium
alveolar
type
ii
pneumocyt
henc
merscov
broader
tissu
tropism
sarscov
mechan
sarscov
merscov
interspeci
transmiss
appear
mediat
protein
mediat
receptor
recognit
membran
fusion
key
factor
host
specif
sever
acut
respiratori
syndrom
sar
first
appear
southern
china
guangdong
provinc
novemb
atyp
commun
pneumonia
within
year
world
health
organ
report
case
death
fatal
countri
five
contin
outbreak
declar
pandem
infect
elderli
subject
signific
comorbid
ill
mortal
rate
investig
reveal
sar
due
novel
coronaviru
sarscov
circul
among
wild
game
anim
wet
market
southern
china
palm
civet
wild
felin
consid
amplif
host
transmit
viru
human
occup
contact
handl
consum
prepar
consumpt
delicaci
sarscov
mainli
spread
human
human
respiratori
droplet
contact
mucosa
contamin
fomit
spread
sarscov
mainland
china
hong
kong
countri
interperson
transmiss
healthcar
facil
home
workplac
public
transport
middl
east
respiratori
syndrom
mer
coronaviru
merscov
first
isol
patient
fatal
pneumonia
septemb
jeddah
saudi
arabia
septemb
juli
report
least
laboratoryconfirm
case
mer
death
fatal
known
case
directli
indirectli
link
countri
arabian
peninsula
howev
outbreak
mer
subsequ
report
south
korea
june
ill
occur
older
man
return
travel
saudi
arabia
within
month
secondari
case
occur
south
korea
connect
index
case
within
month
local
outbreak
result
total
confirm
case
mer
south
korea
except
one
case
export
china
death
attribut
merscov
infect
mortal
rate
postul
primari
mechan
sar
immun
suppress
result
damag
immun
cell
spleen
lymph
node
lymphoid
tissu
sever
lymphopenia
furthermor
gu
et
al
estim
extent
immun
cell
damag
better
predictor
outcom
damag
lung
investig
judg
lung
injuri
subsequ
acut
respiratori
distress
syndrom
ard
pulmonari
fibrosi
primari
event
lead
advers
outcom
death
use
multipl
mode
investig
model
gene
set
proteom
analysi
histopatholog
correl
investig
conclud
urokinas
extracellular
fibrinolyt
pathway
primari
mechan
involv
lung
damag
overal
sarscov
infect
pathogenesi
event
driven
pathway
result
imbal
host
coagul
fibrinolysin
pathway
ultim
lead
diffus
alveolar
acut
lung
damag
like
howev
mechan
involv
pathogenesi
sar
merscov
infect
associ
sever
pneumonia
multiorgan
dysfunct
higher
mortal
rate
sar
recent
studi
compar
viral
replic
cytokinechemokin
respons
antigen
present
merscovinfect
human
monocytederiv
macrophag
mdm
sarscovinfect
mdm
merscov
sarscov
could
replic
human
macrophag
virus
could
stimul
express
antivir
cytokin
interferonalpha
compar
level
tumor
necrosi
factor
tnf
interleukin
il
could
induc
virus
howev
merscov
induc
significantli
higher
level
sever
chemokin
sarscov
addit
express
major
histocompat
complex
hla
class
costimulatori
molecul
greater
merscovinfect
mdm
sarscovinfect
cell
establish
product
infect
macrophag
dendrit
cell
result
impair
antigenpres
pathway
greater
aberr
induct
cytokineschemokin
merscov
could
explain
higher
sever
infect
greater
mortal
sarscov
infect
furthermor
recent
shown
merscov
capac
infect
lymphocyt
induc
apoptosi
cell
activ
extrins
intrins
apoptosi
pathway
merscovderiv
protein
inhibit
express
result
lower
ifn
level
respiratori
tract
lower
express
type
ifn
fatal
case
persist
express
proinflammatori
cytokin
neutrophil
activ
chemotact
respons
result
damag
surround
uninfect
lung
tissu
furthermor
merscov
impair
activ
adapt
immun
multipl
mechan
downregul
antigenpres
pathway
inhibit
activ
tcell
infect
tcell
peripher
blood
lymphoid
organ
tonsil
spleen
extens
apoptosi
tcell
result
impair
tand
bcell
function
helper
tcell
also
affect
spike
nucleocapsid
n
protein
major
immunogen
compon
coronavirus
produc
larg
quantiti
infect
antibodi
n
protein
diagnost
therapeut
potenti
protein
appear
main
determin
protect
immun
crossspeci
transmiss
sarscov
emerg
anim
coronavirus
mice
antibodi
protein
protect
sarscov
challeng
antibodi
n
protein
produc
limit
protect
initi
case
sar
guangdong
outbreak
relat
game
anim
contact
wet
market
handl
consumpt
howev
secondari
case
major
exposur
infect
droplet
contamin
fomit
infect
patient
airborn
transmiss
sarscov
consid
rare
unlik
may
occur
one
commun
outbreak
gener
neg
pressur
exhaust
fan
dissemin
contamin
aerosol
sewag
drain
nosocomi
transmiss
sarscov
major
sourc
outbreak
hong
kong
toronto
enhanc
use
nebul
suction
intub
bronchoscopi
cardiopulmonari
resuscit
gener
high
amount
infecti
droplet
estim
height
sar
pandem
singl
case
result
averag
secondari
case
patient
superspread
viru
could
infect
larger
number
peopl
merscov
infect
outbreak
epidemiolog
strongli
suggest
zoonot
transmiss
intermedi
anim
host
genom
analysi
viru
indic
merscov
aros
bat
coronaviru
support
presenc
small
fragment
genom
sequenc
ident
merscov
essen
isol
egyptian
tomb
bat
taphoz
perforatu
found
saudi
arabia
increas
evid
camel
intermedi
host
respons
crossspeci
transmiss
human
crossreact
antibodi
merscov
found
dromedari
camel
oman
canari
island
egypt
studi
also
confirm
presenc
merscov
rna
realtim
revers
transcriptas
polymeras
chain
reactor
rtpcr
assay
partial
genom
sequenc
viral
rna
nasal
sampl
collect
camel
qatar
two
subject
farm
addit
fatal
case
human
merscov
infect
transmit
contact
infect
camel
rhinorrhea
full
genom
sequenc
isol
patient
camel
ident
recent
report
high
proport
dromedari
slaughterhous
shed
nasal
merscov
highrisk
human
exposur
potenti
drive
epidem
similar
epidemiolog
sar
case
mer
occur
humantohuman
transmiss
respiratori
droplet
contamin
mucosa
infect
fomit
direct
contact
variou
set
direct
evid
airborn
transmiss
infecti
aerosol
household
contact
cluster
associ
index
patient
infect
merscov
saudi
arabia
investig
secondari
transmiss
household
contact
use
serolog
rtpcr
throat
swab
identifi
secondari
transmiss
cluster
secondari
infect
person
transmiss
rate
howev
case
mer
arabian
peninsula
result
transmiss
associ
direct
indirect
contact
healthcar
facil
patient
unrecogn
infect
patient
visitor
healthcar
personnel
largest
singl
outbreak
jeddah
saudi
arabia
major
patient
merscov
infect
contact
healthcar
facil
patient
laboratoryconfirm
merscov
infect
subject
asymptomat
ill
patient
die
overal
mortal
howev
mani
asymptomat
subject
could
recal
symptom
consist
mild
respiratori
infect
ill
symptomat
patient
exclud
healthcar
personnel
contact
healthcar
facil
person
confirm
mer
someon
sever
respiratori
ill
preced
day
onset
ill
largest
outbreak
mer
outsid
middl
east
occur
south
korea
confirm
case
death
healthcar
facil
major
sourc
outbreak
four
hospit
cluster
account
case
investig
isol
ward
found
extens
viabl
merscov
contamin
air
surround
materi
mer
unit
rais
concern
adequaci
current
infect
control
procedur
interhuman
transmiss
merscov
estim
use
bayesian
analysi
calcul
basic
reproduct
number
ro
estim
ro
merscov
confid
interv
ci
wherea
prepandem
sarscov
ro
ci
ro
pandem
potenti
exist
henc
merscov
consid
pandem
potenti
cycl
transmiss
sarscov
merscov
demonstr
fig
b
clinic
featur
sar
mer
similar
usual
mimic
influenza
infect
nonspecif
viral
ill
initi
incub
period
sar
estim
day
case
occur
within
day
exposur
transmiss
symptomat
patient
usual
occur
day
ill
relat
rise
viral
load
nasopharyng
secret
peak
around
day
ill
sar
initi
symptom
fever
chill
myalgia
malais
nonproduct
cough
sore
throat
rhinorrhea
less
frequent
clinic
deterior
sever
ill
usual
occur
sever
day
infect
often
herald
develop
diarrhea
evid
pneumonia
respiratori
distress
common
extrapulmonari
manifest
sar
diarrhea
hepat
dysfunct
cardiac
impair
myositi
seizur
milder
diseas
occur
children
sar
mer
increas
morbid
mortal
seen
elderli
signific
comorbid
ill
diabet
heart
diseas
etc
pregnanc
sever
case
ard
requir
mechan
ventil
renal
failur
complic
survivor
sever
sar
could
develop
residu
pulmonari
fibrosi
muscl
weak
depress
even
month
acut
ill
infect
merscov
result
diseas
clinic
indistinguish
sar
greater
risk
sever
pneumonia
incub
period
also
similar
rang
day
median
time
day
merscov
sarscov
like
transmit
symptomat
patient
viral
concentr
pharyng
secret
asymptomat
mild
infect
low
current
data
indic
peopl
merscov
infect
develop
clinic
ill
symptomat
patient
common
present
fever
laboratori
find
mer
may
includ
leucopenia
lymphopenia
thrombocytopenia
elev
liver
enzym
elev
serum
creatinin
combin
one
system
involv
present
pneumonia
develop
twothird
patient
merscov
infect
could
lead
respiratori
failur
ard
acut
renal
failur
death
sar
outbreak
diagnosi
base
potenti
exposur
individu
sarscov
time
present
acut
febril
flulik
ill
diagnosi
confirm
realtim
rtpcr
nasopharyng
aspir
sensit
first
day
ill
high
specif
antibodi
test
done
variou
method
viru
could
recov
respiratori
secret
fecal
occasion
urin
specimen
viral
cultur
neutral
antibodi
acut
convalesc
sera
week
later
could
confirm
diagnosi
indirect
immunofluoresc
antibodi
test
commonli
use
enzym
immunoassay
eia
use
recombin
nucleocapsid
rapid
screen
test
high
sensit
day
ill
could
crossreact
human
coronavirus
need
western
blot
test
confirm
mer
diagnosi
base
clinic
present
flulik
ill
appropri
epidemiolog
set
recent
travel
arabian
peninsula
countri
local
outbreak
realtim
rtpcr
throat
swab
primari
mean
confirm
diagnosi
serolog
test
use
primarili
epidemiolog
investig
serolog
test
includ
recombin
elisa
use
domain
merscov
spike
protein
recombin
immunofluoresc
assay
full
spike
protein
plaquereduct
neutral
assay
rtpcr
prefer
diagnost
test
acut
case
viru
also
cultur
vero
cell
test
merscov
done
nasopharyng
secret
also
lower
respiratori
secret
serum
detect
viru
found
occas
site
neg
test
upper
respiratori
secret
relat
higher
viral
load
merscov
lower
respiratori
tract
diagnosi
upper
respiratori
tract
recommend
rtpcr
target
upe
orfb
recent
evalu
indic
target
less
sensit
use
diagnosi
extens
data
lung
patholog
immunolog
patient
sar
littl
far
patient
mer
howev
expect
lung
patholog
sever
mer
case
similar
sever
sar
case
patient
die
within
day
onset
sar
diffus
alveolar
damag
edema
promin
find
find
accompani
chang
found
ard
hyalin
membran
interstiti
infiltr
inflammatori
cell
bronchiolar
epitheli
cell
injuri
denud
loss
cilia
fibrin
deposit
exposur
basement
membran
day
ill
patholog
chang
consist
mixtur
acut
chang
reactiv
process
interstiti
airspac
fibroblast
prolifer
type
ii
pneumocyt
hyperplasia
squamou
metaplasia
bronchial
epithelium
alveolar
infiltr
macrophag
desquam
pneumocyt
multinucl
cell
case
reveal
hemophagocytosi
alveolar
exud
thrombosi
venul
rare
one
report
histolog
lung
reveal
vascul
wall
small
vein
edema
fibrinoid
necrosi
infiltr
lymphocyt
monocyt
plasma
cell
patholog
chang
outsid
lung
sar
consist
predominantli
necrosi
atrophi
lymph
node
white
pulp
spleen
even
though
viru
detect
enterocyt
intestin
cellular
damag
inflamm
studi
patient
sever
sar
soon
hospit
shown
decreas
natur
killer
cell
lymphocyt
b
lymphocyt
first
week
sar
intens
inflammatori
respons
elev
proinflammatori
cytokin
high
viral
load
specif
serum
antibodi
detect
indirect
immunofluoresc
neutral
appear
around
day
peak
plateau
second
month
persist
month
limit
data
patholog
immun
respons
merscov
infect
human
one
studi
two
patient
mer
one
die
recov
evid
gener
critic
initi
robust
immun
respons
usual
promot
antigen
present
drive
antivir
immun
respons
mediat
clear
viru
merscov
could
also
upregul
express
human
patient
die
low
regulatori
factor
involv
recognit
viru
wherea
molecul
elev
survivor
addit
elev
chemokin
ligand
level
associ
low
express
nonsurvivor
unclear
report
whether
differ
immun
respons
describ
two
patient
differ
outcom
relat
differ
innat
immun
due
viral
factor
overwhelm
infect
suppress
immun
nonsurvivor
vitro
studi
suggest
merscov
induc
greater
dysfunct
immun
respons
sarscov
downregul
gene
involv
antigen
present
pathway
date
detail
patholog
find
sever
mer
case
probabl
religi
custom
middl
east
clinic
manag
sar
mer
larg
support
care
depend
sever
ill
healthcar
set
prompt
diagnosi
singl
room
accommod
droplet
contact
precaut
necessari
prevent
nosocomi
transmiss
special
precaut
prevent
airborn
transmiss
recogn
import
sar
outbreak
certain
set
hospit
tracheal
suction
use
nebul
bronchoscopi
etc
eye
protect
airborn
precaut
also
appli
care
proven
suspect
merscovinfect
patient
perform
aerosolgener
procedur
antibiot
treatment
possibl
communityacquir
bacteri
pneumonia
usual
implement
diagnosi
coronaviru
infect
confirm
sever
case
sar
mer
usual
requir
intens
care
manag
fluid
electrolyt
disturb
mechan
ventil
respiratori
failur
hemodialysi
renal
failur
case
specif
antivir
agent
immun
modul
corticosteroid
signific
valu
sar
outbreak
although
evid
vitro
activ
sarscov
result
studi
inconsist
vitro
activ
antivir
agent
ribavirin
use
combin
actual
low
howev
report
synergist
activ
combin
ifn
ribavirin
sarscov
pegyl
shown
effect
reduc
viral
load
lung
patholog
earli
treatment
sarscov
infect
nonhuman
primat
model
treatment
sever
case
sar
convalesc
plasma
high
neutral
antibodi
use
question
valu
similar
experi
sar
outbreak
specif
therapi
shown
definit
valu
sever
mer
case
retrospect
cohort
studi
sever
merscovinfect
patient
subject
treat
ribavirin
combin
compar
patient
treat
support
care
improv
surviv
day
day
anoth
recent
report
case
mer
treat
combin
ribavirin
promis
result
overal
mortal
rate
factor
associ
increas
mortal
includ
age
year
nonhuman
primat
model
shown
vari
respons
sarscov
challeng
cynomolgu
macaqu
macaca
fasciculari
demonstr
clinic
patholog
featur
similar
human
infect
sarscov
howev
studi
report
overt
diseas
sarscovinfect
cynomolgu
rhesu
african
green
monkey
african
green
monkey
patholog
demonstr
mild
interstiti
pneumon
resolv
day
divers
rang
anim
shown
suscept
sarscov
infect
includ
palm
civet
pig
raccoon
dog
ferret
golden
syrian
hamster
viral
replic
could
occur
domest
cat
balbc
mice
remain
asymptomat
sever
anim
speci
experiment
infect
merscov
rhesu
macaqu
cynomolgu
macaqu
marmoset
ferret
mice
syrian
hamster
rabbit
dromedari
camel
outcom
develop
lower
respiratori
tract
diseas
quit
variabl
model
infect
rhesu
macaqu
result
transient
clinic
sign
increas
bodi
temperatur
increas
respiratori
rate
cough
local
pulmonari
infiltr
interstiti
mark
visibl
radiograph
imag
histopatholog
day
postinocul
reveal
mildmoder
interstiti
pneumonia
littl
inflamm
septa
thicken
edema
fibrin
intraalveolar
infiltr
macrophag
neutrophil
multinucl
giant
cell
fibrin
slough
epitheli
cell
perivascular
inflammatori
infiltr
interstitium
day
merscov
could
detect
lung
rtpcr
extrapulmonari
organ
oropharyng
rectal
swab
day
postinfect
type
ii
pneumocyt
hyperplasia
alveolar
edema
fibrin
deposit
hyalin
membran
viral
rna
antigen
could
detect
type
ii
pneumocyt
alveolar
macrophag
increas
level
proinflammatori
cytokin
chemokin
matrix
metalloproteinas
found
serum
marmoset
infect
merscov
develop
sever
diseas
clinic
sign
respiratori
distress
progress
interstiti
pulmonari
infiltr
visibl
imag
resolut
day
anim
speci
includ
camel
viru
caus
mild
clinic
diseas
dromedari
camel
nasal
discharg
nasal
excret
viru
present
day
commonli
use
laboratori
anim
mice
syrian
hamster
ferret
suscept
merscov
infect
differ
receptor
dipeptidyl
peptidas
howev
transgen
mice
express
human
develop
demonstr
sever
lethal
respiratori
diseas
merscov
infect
thu
transgen
mice
human
receptor
suitabl
anim
model
studi
new
therapeut
vaccin
merscov
infect
sever
agent
found
vitro
antivir
activ
sarscov
includ
glycyrrhizin
baicalin
reserpin
niclosamid
chloroquin
nelfinavir
never
test
suitabl
anim
model
develop
probabl
cessat
sar
outbreak
case
investig
anim
model
also
demonstr
feasibl
develop
benefici
vaccin
sar
protect
antibodi
respons
could
gener
target
viral
spike
antigen
mucos
immun
african
green
monkey
recombin
attenu
parainfluenzasarscov
spike
protein
chimer
viru
result
signific
neutral
antibodi
protect
viru
replic
upper
lower
respiratori
tract
sarscov
challeng
sever
method
deliv
protein
nucleoprotein
investig
adenovir
vector
rhesu
macaqu
inactiv
whole
viru
vaccin
mice
protein
fragment
mice
rabbit
dna
vaccin
nucleoprotein
mice
plasmid
dna
vaccin
carri
protein
encod
human
codon
mous
model
none
studi
use
anim
model
clinic
pneumonia
show
protect
clinic
diseas
develop
vaccin
pursu
studi
provid
evid
proof
concept
intens
investig
implement
variou
research
center
identifi
new
therapeut
agent
combat
merscov
sinc
recognit
outbreak
middl
east
howev
develop
new
drug
vaccin
take
mani
year
becom
readili
avail
usual
year
pragmat
approach
meet
current
need
demand
near
futur
assess
drug
compound
alreadi
develop
one
studi
vitro
activ
ifn
product
ribavirin
mycophenol
acid
merscov
assess
ifn
test
show
greatest
activ
potent
ribavirin
inhibit
viru
concentr
achiev
dose
use
human
mycophenol
acid
show
mark
inhibit
merscov
howev
mycophenol
mofetil
immunosuppress
properti
use
organ
transplant
patient
could
lead
superinfect
advers
outcom
anoth
studi
group
investig
develop
pharmaceut
compound
screen
vitro
activ
merscov
total
agent
show
antivir
activ
sarscov
merscov
differ
class
pharmaceut
includ
inhibitor
dopamin
receptor
use
antipsychot
inhibitor
estrogen
receptor
use
cancer
treatment
probabl
clinic
relev
studi
repurpos
drug
therapeut
sever
merscov
infect
recent
publish
three
commerci
avail
drug
potent
vitro
activ
merscov
assess
common
marmoset
sever
diseas
resembl
mer
human
lopinavirritonavir
proteas
inhibitor
combin
use
treat
human
immunodefici
viru
hiv
anim
demonstr
significantli
better
outcom
untreat
anim
improv
clinic
radiolog
patholog
find
lower
mean
viral
load
lung
tissu
anim
treat
mycophenol
mofetil
contrast
develop
sever
fatal
diseas
higher
mean
viral
load
untreat
anim
henc
clinic
trial
pilot
assess
patient
sever
mer
warrant
trial
lopinavir
ritonavir
combin
alon
novel
approach
treatment
prevent
sever
mer
use
neutral
monoclon
antibodi
mab
one
mab
design
potent
block
merscov
entri
human
cell
specif
bind
receptorbind
domain
merscov
protein
block
bind
cellular
receptor
thu
develop
human
monoclon
antibodi
could
use
therapeut
prophylact
healthcar
worker
famili
member
expos
patient
merscov
infect
develop
area
includ
isol
potent
merscov
neutral
antibodi
memori
b
lymphocyt
infect
subject
antibodi
label
interf
bind
cellular
receptor
also
could
use
treatment
prophylaxi
particularli
relev
recent
mer
outbreak
south
korea
secondari
tertiari
case
larg
transmiss
nonhealthcar
worker
urgent
need
futur
sever
case
mer
reason
administ
convalesc
sera
previous
infect
recov
subject
mer
shown
experiment
anim
mersimmun
sera
infect
camel
augment
merscov
clearanc
reduc
patholog
chang
infect
lung
although
feasibl
develop
effect
vaccin
merscov
support
recent
experi
subunit
fulllength
merscov
protein
antigen
appear
unlik
occur
case
mer
viru
far
mutat
becom
easili
transmiss
thu
develop
vaccin
would
commerci
viabl
enterpris
although
futur
unpredict
seem
like
merscov
unlik
sarscov
may
continu
caus
sporad
human
infect
local
outbreak
viru
appear
entrench
endem
dromedari
camel
middl
east
also
potenti
spread
maintain
reservoir
anim
region
carri
similar
receptor
hors
goat
sheep
cow
import
howev
prepar
futur
mer
outbreak
zoonot
coronavirus
may
jump
speci
barrier
produc
anoth
novel
unexpect
zoonosi
epidem
order
prevent
futur
coronaviru
zoonosi
emerg
need
basic
research
fulli
understand
mechan
crossspeci
viru
transmiss
current
investig
indic
surfac
protein
coronaviru
host
proteas
cleav
protein
membran
fusion
key
factor
interspeci
transmiss
believ
two
mutat
may
allow
bat
coronaviru
enter
human
cell
enabl
protein
activ
human
proteas
could
environment
extrins
factor
facilit
key
mutat
enabl
crossspeci
transmiss
bat
camel
human
modifi
area
futur
research
rather
develop
specif
agent
treat
merscov
vaccin
prevent
may
fact
would
prudent
develop
new
treatment
prevent
could
effect
zoonot
coronavirus
may
emerg
futur
coronavirus
requir
proteolyt
activ
nsp
proteas
replic
identifi
common
target
develop
gener
anticoronaviru
agent
develop
univers
antivir
agent
anim
coronavirus
may
feasibl
could
difficult
screen
peptidomimet
librari
identifi
compound
good
excel
inhibitori
potenc
bat
coronaviru
anoth
target
multipl
coronavirus
coronaviru
helicas
nsp
also
import
viral
replic
replic
inhibitor
viral
helicas
sarscov
mous
hepat
viru
merscov
may
suitabl
candid
broad
spectrum
coronaviru
inhibitor
design
univers
vaccin
current
futur
zoonot
coronavirus
may
difficult
undertak
neutral
antibodi
spike
glycopro
tein
shown
strain
specif
littl
crossreact
within
across
subgroup
addit
nucleocapsid
protein
share
crossreact
epitop
across
subgroup
coronavirus
propos
vaccin
design
emerg
anim
coronavirus
includ
chimer
spike
protein
contain
neutral
epitop
multipl
strain
across
subgroup
vaccin
manufactur
compani
would
like
entic
seemingli
nonprofit
enterpris
scientist
still
pursu
ventur
even
proof
concept
anim
model
experi
need
univers
coronaviru
vaccin
may
aris
sometim
futur
merscov
lethal
six
known
human
coronavirus
produc
higher
mortal
sarscov
moreov
like
continu
afflict
human
forese
futur
unlik
sarscov
reappear
sinc
first
appear
decad
ago
merscov
use
variou
method
evad
host
innat
antivir
immun
may
explain
high
pathogen
capabl
recent
advanc
understand
immunopathogenesi
mer
may
lead
effect
therapi
although
overal
mortal
clinic
recogniz
case
mer
global
treatment
south
korea
reduc
death
rate
